Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Ultimovacs ASA (ULTI)

Oslo
Currency in NOK
2.28
+0.10(+4.60%)
Real-time Data
ULTI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
2.192.36
52 wk Range
1.57165.00
Key Statistics
Edit
Prev. Close
2.17
Open
2.3
Day's Range
2.19-2.36
52 wk Range
1.57-165
Volume
348.28K
Average Volume (3m)
418.79K
1-Year Change
-98.1%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ULTI Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Ultimovacs Company Profile

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

Compare ULTI to Peers and Sector

Metrics to compare
ULTI
Peers
Sector
Relationship
P/E Ratio
−0.5x−2.4x−0.7x
PEG Ratio
−0.02−0.030.00
Price/Book
0.4x1.7x2.6x
Price / LTM Sales
-10.6x3.2x
Upside (Analyst Target)
166.2%97.9%44.1%
Fair Value Upside
Unlock13.4%8.2%Unlock

Analysts' Recommendations

0 Buy
0 Hold
1 Sell
Ratings:
2 analysts
Overall Consensus
Strong Sell

Analysts 12-Month Price Target:

Average 5.75

(+152.19% Upside)

FAQ

What Is the Ultimovacs (ULTI) Stock Price Today?

The Ultimovacs stock price today is 2.28.

What Stock Exchange Does Ultimovacs Trade On?

Ultimovacs is listed and trades on the Oslo stock exchange.

What Is the Stock Symbol for Ultimovacs?

The stock symbol for Ultimovacs is "ULTI."

What Is the Ultimovacs Market Cap?

As of today, Ultimovacs market cap is 74.83M.

What is Ultimovacs Earnings Per Share?

The Ultimovacs EPS is -4.34.

What Is the Next Ultimovacs Earnings Date?

Ultimovacs will release its next earnings report on 12 Feb 2025.

From a Technical Analysis Perspective, Is ULTI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.